[Asia Economy Reporter Cho Hyun-ui] HanAll BioPharma announced on the 4th that it has recruited CEO Jeong Seung-won, who has 15 years of experience at multinational pharmaceutical companies Novartis and UCB.
New CEO Jeong graduated from Yonsei University College of Medicine and completed an MBA at the MIT Sloan School of Management. He worked for 12 years at the Swiss pharmaceutical company Novartis and led market expansion in Japan and China for UCB.
He will serve as the CEO of HPI, HanAll BioPharma's U.S. subsidiary. He plans to accelerate the global clinical development of new drugs such as HL036 for dry eye syndrome and HL161, an antibody for autoimmune diseases, and also focus on securing new pipelines through open innovation.
New CEO Jeong said, "Based on the experience and know-how I have accumulated so far, I will advance global clinical trials and business development of key pipelines and strengthen the new drug lineup through open collaboration with promising overseas companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
